This article is more than 5 years old. Information may no longer be current.

Patients enrolled in phase 2b trial of adenoviral conjunctivitis candidate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals has enrolled the first patients in Brazil as part of its phase 2b trial of an anti-infective compound as a treatment for adenoviral conjunctivitis, according to a company news release.

The multicenter, randomized clinical study of Auriclosene (NVC-422) ophthalmic solution is designed to determine the compound’s efficacy in clearing the red eye, blurred vision and lingering effects left by an adenoviral infection.

The company intends to enroll about 450 patients with adenoviral conjunctivitis at sites in Brazil, India and the United States. Enrollment has begun in each nation.

NovaBay is working with Quintiles Research in India, Chiltern International in Brazil and Symbio LLC in the U.S. to conduct the trial, dubbed BAYnovation.